Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT.

BACKGROUND: The addition of adjuvant trastuzumab to chemotherapy has significantly improved outcomes for people with human epidermal growth factor receptor 2 (HER2)-positive, early, potentially curable breast cancer. Twelve months' trastuzumab, tested in registration trials, was adopted as stan...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Health Technol Assess
Главные авторы: Earl, Helena, Hiller, Louise, Vallier, Anne-Laure, Loi, Shrushma, McAdam, Karen, Hughes-Davies, Luke, Rea, Daniel, Howe, Donna, Raynes, Kerry, Higgins, Helen B, Wilcox, Maggie, Plummer, Chris, Mahler-Araujo, Betania, Provenzano, Elena, Chhabra, Anita, Gasson, Sophie, Balmer, Claire, Abraham, Jean E, Caldas, Carlos, Hall, Peter, Shinkins, Bethany, McCabe, Christopher, Hulme, Claire, Miles, David, Wardley, Andrew M, Cameron, David A, Dunn, Janet A
Формат: Artigo
Язык:Inglês
Опубликовано: NIHR Journals Library 2020
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7505360/
https://ncbi.nlm.nih.gov/pubmed/32880572
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3310/hta24400
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы